曲美布汀联合黛力新治疗2型糖尿病胃肠功能紊乱患者的效果研究

Effect of Trimebutine Combined with Deanxit on Gastrointestinal Dysfunction in Patients with Type 2 Diabetes

目的分析曲美布汀联合黛力新治疗2型糖尿病胃肠功能紊乱患者的临床效果。方法方便选取2016年1月—2020年12月该院收治的87例2型糖尿病胃肠功能紊乱患者进行研究,采用随机数字表法进行分组治疗。对照组给予维生素B1治疗,观察组给予曲美布汀联合黛力新治疗,记录两组患者治疗前后的生化指标,比较治疗效果。结果观察组治疗后的Cr(76.11±5.19)μmol/L、ALT(32.19±2.97)V/L、BUN(5.39±1.12)mmol/L、CK(85.11±17.99)V/L指标与对照组指标间比较,差异无统计学意义(t=0.018、0.026、0.042、0.003,P>0.05));观察组患者治疗有效率是95.35%,显著高于对照组77.27%,差异有统计学意义(χ^(2)=5.976,P<0.05)。结论针对2型糖尿病胃肠功能紊乱患者,临床选择用曲美布汀联合黛力新治疗的效果是非常明显的,在临床中应该推广和应用。

Objective To analyze the clinical effect of trimebutine combined with Deanxit in the treatment of patients with type 2 diabetic gastrointestinal dysfunction.Methods A total of 87 patients with gastrointestinal dysfunction of type 2 diabetes treated in the hospital from January 2016 to December 2020 were conveniently selected and observed.They were randomly divided into groups,and the control group was treated with vitamin B1,while the observation group was treated with trimebutine combined with Deanxit.The biochemical indexes of the two groups were recorded before and after treatment,and the therapeutic effects were compared.Results Comparison of Cr(76.11±5.19)μmol/L,ALT(32.19±2.97)U/L,BUN(5.39±1.12)mmol/L,CK(85.11±17.99)U/L after treatment with the control group,the difference was no statistically significant(t=0.018,0.026,0.042,0.003,P>0.05).The effective rate in observation group was 95.35%,significantly higher than 77.27%in control group,the difference was statistically significant(χ^(2)=5.976,P<0.05).Conclusion For patients with gastrointestinal dysfunction in type 2 diabetes mellitus,the clinical effect of trimebutine combined with Deanxit is very obvious,which should be popularized and applied in clinic.